anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Spontaneous gastric intramural haematoma is an uncommon complication associated with anticoagulant therapy. A patient receiving chronic warfarin for paroxysmal atrial fibrillation was admitted due to atrial fibrillation with rapid ventricular response (RVR). An incidental intra-abdominal mass was detected on a CT scan. Following the initiation of the amiodarone infusion, the patient experienced bleeding attributed to warfarin-amiodarone-induced coagulopathy, with no identifiable bleeding source. Subsequent CT scans revealed an enlargement of the intra-abdominal mass, suggesting gastric intramural haematoma. After coagulopathy reversal, the haematoma is managed conservatively. Our case underscores the potential for incidental bleeding even when the international normalised ratio is within the normal range in patients on chronic warfarin therapy. When managing such patients with atrial fibrillation with RVR, physicians should maintain a high index of suspicion for bleeding, emphasising the importance of prompt coagulopathy reversal.
PROBLEM TO BE SOLVED: To obtain the subject promoter with nicotinic acid or the like as active ingredient, having such action as to vitalize synthesis of cholesterol or the like by epidermal cells themselves inside the cutaneous surface layer, and therefore having sustainable effect on rough skin improvement owing to skin barrier function recovery, dermatoses therapies and the recovery from barrier function decline associated with senescence. SOLUTION: This promoter contains, as active ingredient, pref. 0.00001-5 wt.% of at least one kind of compound selected from the group consisting of nicotinic acid, derivatives thereof, nicotinic alcohol and salts thereof; wherein the nicotinic acid derivatives are pref. compounds of formula I (R1 is H, OH, NH2 or the like; R2 is absent, an aliphatic monoamine or the like) or formula II (R5 and R6 are each OH or NH2 ) (pref. methylnicotinic acid or the like), while the nicotinic alcohol salts are pref. compounds of formula III (R9 is absent or a monovalent organic acid) (pref. tartaric acid nicotinic alcohol salt or the like).
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to dry, solid oral composition for delivery of drug that is made as multiple of granules. Granules comprise polymeric matrix where from 15 to 70 wt.-% of fat, oily or glue substance are included in combination with pharmaceutically active substance or indicated amount of pharmaceutically active substance that shows fat, oily or glue properties. Polymeric matrix consists of polyethylene glycol or mixture of polyethylene glycols that are solid at environment temperature. Pharmaceutically active substance is peptide drug inhibiting thrombin, dihydropyridine drug or alendronate. Composition elicits properties of rapid release that provides simultaneous delivery of drug and absorption enhancer or solubility enhancer to required site in the high concentration. High gradient of concentration enhances possibility for drug absorption. EFFECT: improved and valuable properties of granules. 11 cl, 5 ex
To date there is no effective way to objectively characterize and predict response to endoscopic dilation of luminal strictures of the GI tract. Endoscopic dilation allows effective remediation of benign esophageal and upper GI tract strictures. Stricture dilation is performed after the stricture diameter is crudely gauged by the endoscopist. Stricture characteristics are based on the severity of symptoms and appearance. A stricture may be graded as mild, moderate, severe and as to whether or not the endoscope is able to traverse the luminal narrowing. By precisely measuring the diameter and length of a stricture, the endoscopist can know exactly what type of dilation is necessary. Benign esophageal strictures may also be refractory to dilation and thus require multiple sessions, prior to achieving successful remediation. The purpose of this study is to investigate the use of a functional luminal imaging probe to characterize benign esophageal luminal strictures before and after dilation and identify predictors of response to therapy. Patients will be evaluated during endoscopy using functional luminal imaging (EndoFLIP; Crospon Medical Devices, Galway, Ireland) to characterize the geometry of benign luminal esophageal narrowing before and after dilation. The study will include patients with strictures referred for endoscopic dilation for the following indications: radiation induced strictures, peptic strictures, RFA induced strictures, EMR induced strictures, eosinophilic esophagitis, Zenkers diverticulum, and strictures related to surgical anastomoses. In patients with benign refractory esophageal strictures referred for endoluminal prostheses EndoFLIP will be used to characterize the stricture prior to stent placement.
Participants will be randomized to follow a diet without soy for 7 days. The diet will be preceded by a 12-hr overnight fast.
PURPOSE: The liver is known to be protected from steatosis under the influence of high GH/IGF-1. Cytokeratin 18 (CK18) and insulin-like growth factor binding protein 7 (IGFBP7) increase in liver steatosis and fibrosis. The aim of this study was to use quantitative ultrasound techniques and biochemical markers to assess liver steatosis and liver fibrosis in newly diagnosed acromegaly.
METHODS: This single-center, cross-sectional study included 23 patients with newly diagnosed acromegaly and 46 age, sex, body mass index (BMI) and waist circumference (WC)-matched controls. Liver steatosis was assessed using tissue attenuation imaging (TAI), and stiffness, indicative of fibrosis, was assessed by shear wave elastography (SWE). Serum IGFBP7 and CK18 were studied by ELISA.
RESULTS: The acromegaly group had significantly lower liver steatosis (p = 0.006) and higher liver stiffness (p = 0.004), serum IGFBP7 (p = 0.048) and CK18 (p = 0.005) levels than the control group. The presence of fibrosis (p = 0.012) was significantly higher in the acromegaly group than in the control group. Moreover, CK18 was positively correlated with liver stiffness, WC, HOMA-IR, HbA1c, and triglyceride. In the acromegaly group, liver steatosis was negatively correlated with GH level. Stepwise multiple linear regression analysis revealed that BMI (p = 0.008) and CK18 (p = 0.015) were independent risk factors for increased liver stiffness.
CONCLUSION: This study showed that there was an increased presence of liver fibrosis independent of liver steatosis in newly diagnosed acromegaly. Serum CK18 appears to be a potential marker of increased liver fibrosis in acromegaly.
FIELD: organic chemistry, medicine, pharmacology, pharmacy. SUBSTANCE: invention proposes a novel analgetic agent. Agent is the known early immunomodulating agents of the general formula (I)   with values of radicals given in description. Experiments in animals have shown effectiveness of agent for treatment of acute, chronic and nociceptive pain. EFFECT: expanded assortment of agents of claimed designation, valuable medicinal property of agent. 6 vl, 3 tests, 1 tbl
Modified proteins, e.g. gelatine, useful in the preparation of blood plasma substitutes, are prepared by causing the free carboxyl groups of the protein to react with the amino groups thereof to cause inter- and intra-molecular cross-linking and subsequently preferentially splitting some of the original peptide bonds. The cross-linking reaction may be brought about by activation of the reacting groups by methods known per se, e.g. the carboxyl groups may be activated with carbodiimidines, e.g. dicyclohexyl- and cyclohexylmorpholinyl ethyl carbodiimide, or with nitrogen analogues of ketenes, whereby the carboxyl groups will react under mild conditions with the amino groups in the protein molecules.  The subsequent splitting of some of the original peptide links may be achieved by chemical means, e.g. with trypsin or acid, or by heat.ALSO:Blood plasma substitutes comprise proteins, e.g. gelatine, which have been modified by causing reaction of the carboxyl and amino groups and consequent inter-and intra-molecular crosslinking and sub-sequently preferentially splitting some of the original peptide linkages (see Division C3). The modified proteins may be dispersed in water and the solutions made isotonic and sterile.
Provided herein are methods, systems, and media for determining a recommended contraceptive by employing clinical decision-making tools to analyze a subject's specific biology (e.g. medical history, mental profile, hormone profile, genetic profiles, menstrual profile). Such tools may discover or analyze biological variables that can be related to side effects and their severities. The methods, systems, and media described herein allow for customized treatment/contraceptive recommends for any subject. In some embodiments, the methods, systems, and media provide information/identification of a hormonal state for a subject. Currently, contraceptive recommendations are primarily based on a one-time “snapshot” of the hormonal profile of the subject at the time the identification assay is administered to the subject. The methods, systems, and media described herein enable the identification of a more transient hormonal state of the subject.
This study is being done to gather data that will be used to compare two different TAC (Temporary Abdominal Closure) methods. The two TAC methods being compared are the Barker's vacuum packing technique or BVPT and the Open Abdomen Negative Pressure Therapy System (ABThera) developed by the sponsor of this research (KCI, San Antonio, TX). The BVPT is made up of supplies that are stocked in most surgery rooms. The ABThera dressing is available commercially. Neither method will be supplied to the doctor (Principal Investigator), so that in no way would the subject's standard of care be different from what they would get if the study was not being done.

This study is observational and only collects data about how the subject progresses after surgery TAC is used. When a study is observational it means that the subject's standard medical care will not be altered in any way, simply watched. The doctor will not change treatment of your open abdomen.
Forty-four patients undergoing laparoscopic cholecystectomy, under general anesthesia, were randomly allocated in two groups. The first group received intravenous lidocaine infusion during the procedure until one hour postoperatively; meanwhile the second group received intravenous saline for the same period of time. The intervention was double-blind. In the postoperative period, both groups received dipyrone and morphine PCA. Pain was assessed by Visual Numeric Scale (VNS) at rest and when coughing at 1st, 2nd, 4th, 12th e 24th hour after the end of the surgery. Blood samples for cytokines measurement were taken at the end of procedure and 24 hours later. The total morphine PCA demand, the time for the first flatus and the length of hospital stay were also recorded and compared.
1,240,546. Medicines containing antibiotics and sulphonamides. RESEARCH CORP. 16 July, 1968 [17 July, 1967], No. 49459/70. Divided out of 1,240,545. Heading A5B. A pharmaceutical composition comprises a heavy metal salt of an antibiotic in admixture with a heavy metal salt of a sulphonamide and/or silver salicylate. The heavy metal salts may be those of gold, nickel, tin, zinc, mercury, platinum, osmium, molybdenum, titanium, copper or silver (preferred). Specified are silver salts of penicillin, cephalothin, colistimethate, and tetracycline; and silver salts of sulphamerazine, sulphonanilide, sulphathiazole, sulphapyridine, sulphamylon, sulphoxazole, sulphapyrimidine, sulphaquinoxaline, substituted benzene sulphonamide and sulphamyl benzothiadiazine dioxide. The compositions may be in the form of a powder, an aqueous suspension, ointment, aerosol or may be incorporated in a film-forming material. Aqueous solutions containing chloride ions e.g. NaCl may be used as carriers for the active ingredients. Specification 1,240,545 is referred to. The compositions are useful in the treatment of burns.
Augmentative and alternative communication (AAC) is a core component of speech pathology practice. However, international literature has highlighted that speech language pathologists (SLPs) may not feel confident or competent in this area. Confidence and competence are critical factors in therapy as they can impact the quality-of-service provision. The purpose of this scoping review was to investigate the confidence/competence of SLPs in AAC. A systematic scoping search was conducted using four databases to identify relevant literature. The first two authors reviewed 30% of abstracts and the remaining 70% were reviewed by the first author. Full-text screening applied the same review approach. Data was then extracted and organized according to the research questions. Thirteen studies were included in the review. All thirteen used self-assessment to measure confidence or competence with one study also using an objective evaluation. Overall, confidence and competence levels varied based on the specific clinical task and etiology of the client in addition to being influenced by prior training, clinician age, workplace and AAC caseload. While current research provides a snapshot of the SLP workforce, it is limited in that the research predominantly uses self-assessment measures, is cross-sectional and is quantitative in nature. Further research into the confidence and competence of SLPs in AAC is required, specifically how confidence and competence can be defined and developed.
The group that starts with the traditional diet in the first 4-week diet period. After wash-out, this group will start with the moderate carbohydrate diet in the second 4-week diet period.
Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
On the basis of the patient's original eating habits, basic dietary and lifestyle guidance is given, and at the same time, nutritional supplements(Ivital Control) are given to instead a meal per day. 2 bags once a day until the end of the visit.
Fenofibrate, is a lipid regulating agent available as tablets for oral administration. Each tablet contains 54 mg or 160 mg of fenofibrate. The chemical name for fenofibrate is 2-[4-(4-chlorobenzoyl) phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester with the following structural formula:

The empirical formula is C20H21ClO4 and the molecular weight is 360.8; fenofibrate is very soluble in methylene chloride, slightly soluble in alcohol and practically insoluble in water. The melting point is 79 to 82°C. Fenofibrate is a white or almost white, crystalline powder, non-hydroscopic which is stable under ordinary conditions. 

Each fenofibrate tablet USP, contains the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose 2910, lactose monohydrate, microcrystalline cellulose, simethicone emulsion (30%), sodium lauryl sulphate, sodium starch glycolate and sodium stearyl fumarate. The film-coating material contains polyethylene glycol 3350, polyethylene glycol 6000, polyvinyl alcohol, talc and titanium dioxide.

Each fenofibrate tablet USP, 54 mg contains iron oxide yellow as an additional film coating ingredient.

Fenofibrate tablet USP complies as per USP dissolution test 3.
Management of large acute corneal hydrops (ACH) has always been a challenge. Various medical and surgical management options have been used, such as topical steroids, cycloplegics, antiglaucoma medications, antibiotics, Descemet's membrane reposition, and pre-Descematic sutures, for the management of acute hydrops, but have shown limited benefit. We hereby describe a novel technique of appositional continuous overlay sutures along with air tamponade for surgical management of corneal edema following large ACH. In this technique, the epithelium is scraped to visualize the stromal cleft, and then corneal marking is done to locate the suture placement site. Next, a continuous overlay, 10-0 nylon suture is passed in a crisscross fashion, just like the laces of a corset. A small paracentesis is made to lower the intraocular pressure. Stromal fluid is milked out using two iris spatulas, simultaneous suture tension adjustment is done, and the knot is secured. Appropriate anterior chamber tamponade is achieved using air, paracentesis is hydrated, and a bandage contact lens is applied. We noted complete resolution of corneal edema within 2 weeks of the procedure, with significant improvement in visual acuity.
Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
Intratumor heterogeneity underlies cancer evolution and treatment resistance, but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all medical therapies, and high-grade meningiomas have significant intratumor heterogeneity. Here we use spatial approaches to identify genomic, biochemical and cellular mechanisms linking intratumor heterogeneity to the molecular, temporal and spatial evolution of high-grade meningiomas. We show that divergent intratumor gene and protein expression programs distinguish high-grade meningiomas that are otherwise grouped together by current classification systems. Analyses of matched pairs of primary and recurrent meningiomas reveal spatial expansion of subclonal copy number variants associated with treatment resistance. Multiplexed sequential immunofluorescence and deconvolution of meningioma spatial transcriptomes using cell types from single-cell RNA sequencing show decreased immune infiltration, decreased MAPK signaling, increased PI3K-AKT signaling and increased cell proliferation, which are associated with meningioma recurrence. To translate these findings to preclinical models, we use CRISPR interference and lineage tracing approaches to identify combination therapies that target intratumor heterogeneity in meningioma cell co-cultures.
SNS-101 IV alone every 21 days. Patients will initially enroll in dose escalation cohorts.
The dose of oral voriconazole is 200 mg twice daily. When voriconazole must be given intravenously, it will be given at a dose of 200 mg every 12 hours for the duration of intravenous therapy.
Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
The invention provides a doxorubicin lipid microbubble. The doxorubicin lipid microbubble comprises a lipid bilayer membrane, gas, albumin nanoparticles for carrying doxorubicin; and the gas and the albumin nanoparticles for carrying the doxorubicin are wrapped by the lipid bilayer membrane. The doxorubicin lipid microbubble has the relative higher medicine loading capacity and the relative higher encapsulation efficiency; the blood concentration of target positions can be improved; the action time of medicines at the target positions is prolonged; the medicine degradation is reduced; and the medicine stability is improved. In addition, the nanoparticles have the beneficial effects that the selective distribution of the medicines is promoted; the medicines are better transmitted to enter lesion tissues; the pesticide effect can be improved; and the toxic and side effects can be reduced. The invention further discloses a preparation method of the doxorubicin lipid microbubble. The preparation process is simple; industrialization is easily achieved; the preparation process does not relate to chemical reactions; organic solvents with high toxicity are not adopted; the safety performance is high; and the environment friendliness is high.
The present invention relates to a method for preparing youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk with micron sugar American ginseng and micron tremella. The youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk is formed by that raw material such as the micron American ginseng, the micron tremella, micron chromium nicotinate powder, micron asparagus, micron nacre powder, xylo-oligosaccharide powder, intestinal tract beneficial bacteria, etc. processed through high-technology airflow superfine grinding are added into different traditional milk liquor, combined and fermented. The youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk has the obvious functions of reducing blood sugar and simultaneously has the effects of keeping youthfulness, moistening lungs, tranquilizing, improving eyesight, allaying fatigue, enhancing immunity, etc. Diabetics can obtain scores of nutrient substances such as abundant protein, vitamins, mineral substances, active ferment, etc., and simultaneously, the youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk can perform the functions of beautifying faces, keeping youthfulness, moistening lungs and reducing blood sugar because the ingredients of chromium nicotinate, etc. which are extolled as blood sugar reducing factors are added. Therefore, the present invention is a favorable method for preparing the youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk for protecting health and prolonging life, and the youthfulness-keeping, lung-moistening and blood sugar-reducing sour milk has Chinese characteristics and is especially designed for middle-aged diabetics and old diabetics all over the world.
The invention relates to application of gingkolic acid in preparation of an external preparation for treating osmidrosis. The gingkolic acid comprises ginkgoic acid, ginkgol, ginkgo diphenol and the like, and can be extracted from leaf, fruit, external exotesta, rhizome and other parts of ginkgo through a chemical separation method. The osmidrosis includes the osmidrosis of axillary part, foot part, perineum and other parts. The drug, cosmetic or disinfectant external preparation containing gingkolic acid for treating osmidrosis contains 0.001-80wt% of gingkolic acid and a pharmaceutically common external preparation matrix or acceptable carrier; and the preparation is any one pharmaceutically external dosage form. Pharmacological experiment researches show that the external preparation has the effects of inhibiting the growth and propagation of bacteria on skin surface and permeating into skin to destroy large sudoriferous gland, and inhibiting the generation of free fatty acid, ammonia nitrogen compound and other smelling substances in sweat. Clinical trial shows that the external preparation has significant treatment effect on the osmidrosis, has effective rate up to 100%, is safe to use and has no side effect.
<P>PROBLEM TO BE SOLVED: To provide a cell image analyzer that quantifies the cell movement distance and vector information by using cell images obtained by photography.  <P>SOLUTION: Each cell image obtained by photographing cells cultured in a cell culture dish equipped with a fixed line pattern with changing time is prepared. When a point on a cell photographed on a cell image preceding in time and a point on the same cell photographed on a cell image later in time are designated by a position designation means 30, a designation position definition means 41 defines the two designated points as the movement start position and the movement end position. The movement distance calculation means 42 calculates the movement distance using the defined movement start position, the defined movement end position and the reduced scale of the photographed image. A vector information calculation means 43 calculates the vector information by utilizing the gradient of a line connecting the defined movement start position to the defined movement end position. Thus the movement of the cell is quantified.  <P>COPYRIGHT: (C)2010,JPO&INPIT